Cardiomyopathies - From Basic Research to Clin. Mgmt.

00_preface_Cardiomyopathies - From Basic Research to Clinical Management......Page 1
00x_part1......Page 15
01_Classification and Definitions of
Cardiomyopathies......Page 17
02_Management of Hypertrophic Obstructive
Cardiomyopathy with a Focus on
Alcohol Septal Ablation......Page 35
03_Hypertrophic Cardiomyopathy
in Infants and Children......Page 47
04_Quality of Life in Dilated Cardiomyopathy with
Refractory Chronic Heart Failure Undergoing
Devices Implantation......Page 83
05_Peripartum Cardiomyopathy:
A Systematic Review......Page 97
06_Cardiomyopathy Detection from
Electrocardiogram Features......Page 131
07_Prevention of Sudden Cardiac Death in
Patients with Cardiomyopathy......Page 149
08_Biomarker for Cardiomyopathy-B-Type
Natriuretic Peptide......Page 181
08x_part2......Page 197
09_Heart Muscle and Apoptosis......Page 199
10_Cardiac Myocytes and Mechanosensation......Page 215
11_Dobutamine-Induced Mechanical Alternans......Page 227
12_MicroRNAs Telltale Effects on Signaling
Networks in Cardiomyopathy......Page 237
13_Intercellular Connections in the Heart:
The Intercalated Disc......Page 259
14_Familial Hypertrophic Cardiomyopathy-Related
Troponin Mutations and Sudden Cardiac Death......Page 291
15_Consequences of Mutations in Genes Encoding
Cardiac Troponin C, T and I – Molecular Insights......Page 317
16_
Cardiomyopathies Associated with
Myofibrillar Myopathies......Page 367
17_Functional Consequences of Mutations in the
Myosin Regulatory Light Chain Associated with
Hypertrophic Cardiomyopathy......Page 397
18_Role of Genetic Factors in
Dilated Cardiomyopathy......Page 423
18x_part3......Page 437
19_Role of Advanced Cardiac Magnetic Resonance
Imaging in Atypical Cardiomyopathies such as
Stress-Induced Cardiomyopathie and
Left-Ventricular Non-Compaction
Cardiomyopathy......Page 439
20_The Use of Contrast-Enhancement
Cardiovascular Magnetic Resonance Imaging in
Cardiomyopathies......Page 453
20x_part4......Page 475
21_The Evolving Face of Heart Failure Associated
with Elevated Cardio-Metabolic Risk Factors......Page 477
22_Diabetic Cardiomyopathy:
Cardiac Changes, Pathophysiological
Mechanisms, Biologic Markers, and the
Available Therapeutic Armamentarium......Page 501
23_Insulin Resistance and Cardiomyopathy......Page 527
24_Taurine Depletion-Related
Cardiomyopathy in Animals......Page 551
25_Thyrotoxic Cardiomyopathy......Page 567
26_Drug-Induced Cardiomyopathies......Page 595
27_Anthracycline Cardiotoxicity......Page 635
28_Cardiotonic Steroids and Cardiac Fibrosis......Page 659
28x_part5......Page 677
29_Stress-Induced Cardiomyopathy:
Clinical Observations......Page 679
30_Takotsubo Cardiomyopathy......Page 697
31_Pathology of Takotsubo (Ampulla)
Cardiomyopathy......Page 723
32_Torsades de Pointes in Takotsubo
Cardiomyopathy with QT Prolongation......Page 741
33_Torsades de Pointes Associated with
Takotsubo Cardiomyopathy: Is It Preventable?......Page 751
33x_part6......Page 761
34_Chagas Heart Disease......Page 763
35_Chagasic Cardiomyopathy
......Page 789